Evidence map›Paper›PMID 24889025›Full record

ArticleScientific reports2014

Synergism and rules of the new combination drug Yiqijiedu formulae (YQJD) on ischemic stroke based on amino acids (AAs) metabolism.

Jian Gao, Chang Chen, Jian-Xin Chen, Li-Mei Wen, Geng-Liang Yang, Fei-Peng Duan, Zhi-Ying Huang, De-Feng Li, Ding-Rong Yu, Hong-Jun Yang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The NLRP3 inflammasome and stroke.International journal of clinical and experimental medicine · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Jian Gao1] Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700 [2] School of Pharmacy, Hebei University, Hebei Baoding 071002 [3].
Chang Chen1] Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700 [2].
Jian-Xin Chen1] Beijing University of Chinese Medicine 100029 [2].
Li-Mei WenCollege of life science and engineering, Southwest Jiaotong University, Sichuan Chengdu 610031.
Geng-Liang YangSchool of Pharmacy, Hebei University, Hebei Baoding 071002.
Fei-Peng DuanBeijing University of Chinese Medicine 100029.
Zhi-Ying HuangSchool of Pharmacy, China Pharmaceutical University, Jiangsu Nanjing 210009.
De-Feng LiInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700.
Ding-Rong YuInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700.
Hong-Jun YangInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700.
Shao-Jing Li1] Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700 [2] Beijing University of Chinese Medicine 100029.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNBeijing University of Chinese Medicine · CNChina Pharmaceutical University · CNHebei University · CNSouthwest Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of combination drugs is considered to be a promising strategy to control complex diseases such as ischemic stroke. The detection of metabolites has been used as a versatile tool to reveal the potential mechanism of diverse diseases. In this study, the levels of 12 endogenous AAs were simultaneously determined quantitatively in the MCAO rat brain using RRLC-QQQ method. Seven AAs were chosen as the potential biomarkers, and using PLS-DA analysis, the effects of the new combination drug YQJD, which is composed of ginsenosides, berberine, and jasminoidin, on those 7 AAs were evaluated. Four AAs, glutamic acid, homocysteine, methionine, and tryptophan, which changed significantly in the YQJD-treated groups compared to the vehicle groups (P < 0.05), were identified and designated as the AAs to use to further explore the synergism of YQJD. The result of a PCA showed that the combination of these three drugs exhibits the strongest synergistic effect compared to other combination groups and that ginsenosides might play a pivotal role, especially when combined with jasminoidin. We successfully explored the synergetic mechanism of multi-component and provided a new method for evaluating the integrated effects of combination drugs in the treatment of complex diseases.

Indexed as

Amino AcidsAnimalsBiomarkersBrainBrain IschemiaDrug CombinationsDrugs, Chinese HerbalDrug SynergismMaleRatsRats, Sprague-DawleyReproducibility of ResultsSensitivity and SpecificityStrokeTreatment OutcomeAmino AcidsBiomarkersDrug CombinationsDrugs, Chinese Herbal

Identifiers

PMID24889025
PMCPMC4042126
OpenAlexW1977887836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.